Fig. 2: Activation of mice and human DCs in the presence of COFs and RNA-seq dataset.
From: Crystallinity of covalent organic frameworks controls immune responses
a In the presence of LPS, mouse DCs treated with COF1 with OVA expressed higher CD86 + , in vitro (mean ± s.d, n = 6 technical replicate; one-way ANOVA test). b DCs treated with COF1 with OVA had lower gMFI CD163+ in CD11c+ compared to other treatments, with inflammation, in vitro (mean ± s.d, n = 6 technical replicate; one-way ANOVA test). c High expression of CD206+ in CD11c+ in presence of COF1 with OVA compared to COF 5 with OVA, LPS, and soluble OVA, in vitro (mean ± s.d, n = 6 technical replicate; one-way ANOVA test). d COF 1 with OVA increase cross-presentation of 257–264 SIINFEKL OVA peptide in DC, with inflammation, in vitro (mean ± s.d, n = 6 technical replicate; one-way ANOVA test). e Volcano plot of COF3 vs COF1, n = 3 biological replicate; one-way ANOVA test. COF1. f Volcano plot of COF5 vs. COF1, n = 3; one-way ANOVA test. g Volcano plot of COF5 vs. COF3, n = 3; one-way ANOVA test. h–j WikiPathways of COF3 vs. COF1, COF5 vs. COF1, COF3 vs. COF5 respectively, n = 3; one-way ANOVA test. k–m Gene Ontology (GO) analysis of COF3 vs. COF1, COF5 vs. COF1, COF3 vs. COF5 respectively, n = 3 biological replicate; one-way ANOVA test. n Higher expression of CD86+ in human dendritic cells treated with COF1 compared to COF5 (in presence of soluble OVA and LPS, mean ± s.d, n = 6 biological replicate; one-way ANOVA test). o COF1 with LPS and soluble OVA can upregulate expression of CD206+ (mean ± s.d, n = 6 biological replicate; one-way ANOVA test). p An increase of the ratio of CD86+ gMFI to CD206+ gMFI in COF1 with ova compared to COF5 (mean ± s.d, n = 6 biological replicate; one-way ANOVA test). All significant differences are not shown for clarity.
